Yorvipath
Active substance: palopegteriparatide
INJECTION, SOLUTION · PALOPEGTERIPARATIDE 294 ug/.98mL
United StatesActive
Marketing holder: Ascendis Pharma, Endocrinology, Inc.
Verified 2026-10-09 · openFDA NDC
Analogues in other countries- Source: openFDA NDC
- Countries with the substance registered: 2
Composition
- PALOPEGTERIPARATIDE · 294 ug/.98mL
Analogues by country
Products with the same active substance registered in other countries.
| Country | Products |
|---|---|
| EU 1 |
|
Import and control
Control by country
- United Statesprescription only
Source: openFDA NDC · record 01a1208c-2ecc-731b-9480-4e5dd6b97971,01a12090-f064-7828-afb4-a7c4c406309f,01a12095-1cf6-7cbc-98c4-4cd5bdebf704;count=3 · valid from 2026-10-09 · verified 2026-10-09
Registration
- Registration number
- 73362-101
- Registration status
- Active
- Dispensing
- Prescription only
- Route
- SUBCUTANEOUS
Sources
- product · openFDA NDC · 73362-101 · Verified 2026-10-09 · open in source
- registration_status · openFDA NDC · 73362-101 · Verified 2026-10-09 · open in source
- ingredients.0 · openFDA NDC · 73362-101 · Verified 2026-10-09 · open in source